Kate Sears

🩸 #ASH26 | #ALL abstracts to watch 👀 My picks from this year’s oral ALL sessions, spanning in vivo T-cell engagement, next-gen CAR-T, T-ALL, salvage after CAR-T, older adults, Ph+ ALL, and MRD-guided therapy. A thread 🧵👇 #373 | Sentry-CD19 First-in-human in vivo gene-encoded CD19×CD3 T-cell engager in R/R B-cell malignancies. → Both B-ALL pts achieved MRD negativity → Grade 4 ICANS was a DLT 📅 Sat Dec 12 | 4:00 PM #374 | SUMM1T Third-generation CD19 CAR-T naricabgene autoleucel in R/R B-ALL/B-NHL. → 19/19 B-ALL achieved CR/CRi → 12-mo PFS: 82.1% 📅 Sat Dec 12 | 4:15 PM #375 | Nanotrident-2 CD19/CD22 tandem CAR-T for B-ALL refractory to prior blinatumomab, inotuzumab or single-target CAR-T. → ORR 91.1% → IEC-HS: 22.2% An important strategy for immune-refractory disease. 📅 Sat Dec 12 | 4:30 PM #378 | SWOG S1905 OBI-3424 in R/R T-ALL. Important negative study: → No CR/CRi at the MTD Not every “abstract to watch” needs to be positive. Negative trials help define where we go next. 📅 Sat Dec 12 | 5:15 PM #764 | Salvage after CART19 What happens when pediatric/AYA B-ALL relapses after CD19 CAR-T? → Median OS from relapse: 15 mo → Inotuzumab and CART22 provided the best salvage outcomes Highly relevant to post-CAR-T sequencing. 📅 Mon Dec 14 | 10:45 AM #894 | Older adults with ALL GMALL registry experience with pediatric-based chemotherapy + stepwise incorporation of immunotherapy. → OS improved from 45% → 70% across treatment eras A compelling look at how immunotherapy is reshaping treatment for older adults. 📅 Mon Dec 14 | 4:00 PM #998 | Blinatumomab + asciminib Phase I/II study in newly diagnosed or R/R Ph+ ALL. → 17 pts → All achieved CR → Asciminib 200 mg selected as RP2D A chemotherapy-light/targeted approach worth following. 📅 Mon Dec 14 | 4:45 PM #1000 | E1910 Does blinatumomab still matter when highly sensitive NGS says MRD-negative? → Benefit seen in both molecular MRD-negative and MRD-positive pts → OS HR 0.31 in both groups Potentially practice-informing data on how we interpret deep MRD negativity. 📅 Mon Dec 14 | 5:15 PM #1002 | ATRIALL / GRAALL-2014/T Nelarabine-based consolidation + maintenance in frontline high-risk adult T-ALL. → 4-yr DFS 65.1% vs 53.6% → Difference not statistically significant Important final data for defining nelarabine’s role in adult T-ALL. 📅 Mon Dec 14 | 5:45 PM Lots to follow at #ASH26 in ALL. What’s on your must-see list? #ALLsm #Leusm #ASH2026 @oncodaily @OpenMedKate @Larvol